Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Paying users zone. Data is hidden behind: .

  • Get 1-month access to Regeneron Pharmaceuticals Inc. for $13.99, or

  • get full access to the entire website for at least 3 months from $49.99.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey
Unlock

This is a one-time payment. There is no automatic renewal.

Regeneron Pharmaceuticals Inc. pages available today for free:

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Beginner level

Regeneron Pharmaceuticals Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Accounts payable
Accrued payroll and related costs
Accrued clinical trial expense
Accrued sales-related charges, deductions, and royalties
Income taxes payable
Other accrued expenses and liabilities
Accrued expenses and other current liabilities
Finance lease liabilities, current portion
Deferred revenue from Sanofi, current portion
Deferred revenue, other, current portion
Convertible senior notes, current portion
Current liabilities
Finance lease liabilities, excluding current portion
Deferred revenue from Sanofi
Deferred revenue, other
Other noncurrent liabilities
Noncurrent liabilities
Total liabilities
Preferred Stock, $.01 par value; issued and outstanding - none
Class A Stock, convertible, $.001 par value
Common Stock, $.001 par value
Additional paid-in capital
Retained earnings
Accumulated other comprehensive income (loss)
Treasury Stock, at cost
Stockholders’ equity
Total liabilities and stockholders’ equity

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Regeneron Pharmaceuticals Inc.’s current liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Regeneron Pharmaceuticals Inc.’s noncurrent liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2017 to 2018 and from 2018 to 2019.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Regeneron Pharmaceuticals Inc.’s total liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2017 to 2018 and from 2018 to 2019.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Regeneron Pharmaceuticals Inc.’s stockholders’ equity as a percentage of total liabilities and stockholders’ equity increased from 2017 to 2018 and from 2018 to 2019.